Raymond James analyst Steven Seedhouse upgraded Dianthus Therapeutics (NASDAQ: DNTH) from Outperform to Strong Buy with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades